Belite Bio, Inc. (NASDAQ:BLTE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET

Company Participants

Tom Lin - Chairman and Chief Executive Officer
Hendrik Scholl - Chief Medical Officer
Nathan Mata - Chief Scientific Officer
Hao-Yuan Chuang - Chief Financial Officer

Conference Call Participants

Basma Radwan - Leerink Partners
Jennifer Kim – Cantor
Yi Chen - H.C. Wainwright
Michael Okunewitch - Maxim Group

Operator

Hello, and thank you for joining us to discuss Belite Bio's Third Quarter 2024 Financial Results. Joining the call today are Dr. Tom Lin, Chairman and CEO of Belite Bio; Dr. Hendrik Scholl, Chief Medical Officer; Dr. Nathan Mata, Chief Scientific Officer; and Hao-Yuan Chuang, Chief Financial Officer.

Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Please note that you can submit questions throughout the call by clicking on the Q&A box at the bottom of your screen, and we will respond to questions following our prepared remarks.

Now I'll turn the call over to Dr. Lin.

Tom Lin

Thanks, Julie. Thank you, everyone, for joining our third quarter conference call. Before diving into the details, of this quarter's performance and status of our pipeline, I would like to introduce an exciting addition to our leadership team. It is my pleasure to welcome Dr. Hendrik Scholl, our new Chief Medical Officer, to the call.

Professor Scholl is the world's foremost expert in Stargardt disease and age-related macular degeneration. He has pioneered some of the most significant ophthalmology and retinal disease advancements of our time, including the world's largest ever natural history study of Stargardt disease. We're thrilled to have him lead our clinical program at such a pivotal time. Certainly, his expertise and dedication will be instrumental in advancing our efforts to bring much needed treatments to patients living with Stargardt disease and dry AMD. Dr. Scholl, welcome.

Hendrik Scholl

Thank you, Tom. I'm honored to be joining Belite Bio at a time when the company's clinical programs are showing such promise. Having served as the chair of the data and safety monitoring board for Belite Phase II and Phase III Stargardt disease trials, I feel immensely confident in Tinlarebant 's potential. I have dedicated my career by improving the lives of people suffering from serious retinal, and specifically macular diseases, which are almost always debilitating and have a profound negative impact on the people's quality of life. I'm deeply impressed by Belite Bio’s pioneering approach to Stargardt disease and late dry AMD, which have historically lacked effective treatment options.